Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology
JAMA · 13.11.2026
DOI: 10.1001/jama.2026.24689 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, online erschienen am 13.11.2026. Verfasst von Kanta Horie und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University School of Medicine, St Louis, Missouri. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Neurodegenerative diseases with abnormal tau protein aggregation in the brain (ie, tauopathies) can be classified by the tau isoform that accumulates: 3-repeat (3R), 4-repeat (4R), or mixed 3R/4R tauopathies, which include chronic traumatic encephalopathy (CTE), some forms of frontotemporal lobar degeneration, and Alzheimer disease (AD). The endogenously cleaved form of tau microtubule binding region containing the residue 243 (eMTBR-tau243) can be detected in cerebrospinal fluid (CSF) and blood and has been associated with AD tau pathology, but its specificity and biological interpretation in non-AD tauopathies remains unclear.
Objective
To evaluate biofluid eMTBR-tau243 in a range of tauopathies. Design, Setting, and Participants This case-control study included 4 biorepositories based in the US that contributed CSF and plasma samples from participants with and without tauopathies, many of whom had antemortem biofluid samples paired with autopsy or genetically defined neuropathology. Samples were analyzed between August 2023 and December 2025. Data analysis occurred from August 2024 to July 2026. Exposure CSF and plasma eMTBR-tau243 concentrations measured using a mass spectrometry–based assay. Main Outcomes and Measures Outcomes included mixed 3R/4R tauopathy (eg, AD and CTE) based on autopsy, frontotemporal lobar degeneration with MAPT variants (FTLD- MAPT ), and CTE stage. Differences in biomarker levels between groups were evaluated using analysis of variance or analysis of covariance, and area under the receiver operating characteristic curve (AUC) was calculated to evaluate the discriminative performance of fluid eMTBR-tau243.
Results
Among the 229 participants (196 with CSF samples and 55 with plasma samples [22 with both]), mean (SD) age at fluid sample collection was 63 (13) years and 108 (47%) were female. Median (IQR) CSF eMTBR-tau243 was increased in 10 patients with AD (0.459 [0.246-0.801] fmol/mL) compared with 29 cognitively unimpaired controls (0.002 [0.001-0.005] fmol/mL) (adjusted P < .001), but other autopsy-confirmed non-AD tauopathies (which included 52 individuals with conditions including progressive supranuclear palsy and corticobasal degeneration) did not demonstrate an increase (0.015 [0.008, 0.039] fmol/mL). Six symptomatic FTLD- MAPT variant carriers with mixed 3R/4R tauopathy (R406W, V337M, and G389R) had increased median (IQR) CSF eMTBR-tau243 (0.140 [0.055-0.174] fmol/mL) compared with 15 4R tauopathy variant carriers including N279K and P301L (0.004 [0.001-0.044] fmol/mL) ( P = .001). Median (IQR) plasma eMTBR-tau243 was increased in 11 patients with CTE (1.93 [0.42-3.68] fmol/L) compared with 20 cognitively unimpaired controls (0.29 [0.05-0.62] fmol/L) (adjusted P = .007), but did not increase as high as among 14 patients with AD (11.25 [2.29-19.38] fmol/L). Plasma eMTBR-tau243 distinguished CTE stage III and IV from controls (AUC, 0.97; 95% CI, 0.92-1.00), but not CTE stage I from controls (AUC, 0.64; 95% CI, 0.32-0.97). Conclusions and Relevance This study found that plasma and CSF eMTBR-tau243 were increased in mixed 3R/4R tauopathies including AD, high-stage CTE, and a subset of genetic FTLD- MAPT , compared with cognitively unimpaired controls. Further validation in larger cohorts is needed to determine the clinical utility of eMTBR-tau243 as a potential diagnostic biomarker for CTE and other tauopathies beyond AD.
Autor:innen und Institutionen
- Department of Neurology, Washington University School of Medicine, St Louis, Missouri.
- Tracy Family SILQ Center, Washington University School of Medicine, St Louis, Missouri.
- Eisai Inc, Nutley, New Jersey.
- Edward and Pearl Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco.
- Department of Clinical and Health Psychology, 1Florida Alzheimer Disease Research Center, Fixel Institute for Neurological Diseases, University of Florida, Gainesville.
- Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri.
Zitieren
APA
Horie, K., Koppisetti, R. K., VandeVrede, L., Asken, B. M., Li, Y., Yen, D., Ghoshal, N., Paterson, R. W., Lario Lago, A., Seeley, W. W., Grinberg, L. T., Bateman, R. J., Boxer, A. L., Spina, S., & Sato, C. (2026). Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology. JAMA. https://doi.org/10.1001/jama.2026.24689
Vancouver
Horie K, Koppisetti RK, VandeVrede L, Asken BM, Li Y, Yen D, et al. Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology. JAMA. 2026. doi:10.1001/jama.2026.24689
BibTeX
@article{Horie2026,
author = {Horie, Kanta and Koppisetti, Rama K and VandeVrede, Lawren and Asken, Breton M and Li, Yan and Yen, Daniel and Ghoshal, Nupur and Paterson, Ross W and Lario Lago, Argentina and Seeley, William W and Grinberg, Lea T and Bateman, Randall J and Boxer, Adam L and Spina, Salvatore and Sato, Chihiro},
title = {Fluid eMTBR-tau243 as a Biomarker of Mixed 3-Repeat and 4-Repeat Tau Pathology},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.24689}
}
EUVIMED